Coherus Oncology (CHRS) Price to Sales (2014 - 2026)

Coherus Oncology has disclosed Price to Sales across 12 years of filings, most recently posting 15.12 for Q2 2026.

• In Q2 2026, Price to Sales rose 82.69% year-over-year to 15.12; the TTM figure through Jun 2026 stood at 4.25 (up 58.32% YoY), while the FY2025 annual figure was 4.08, down 32.53% from the prior year.
• Price to Sales came in at 15.12 for Q2 2026 at Coherus Oncology, down from 21.17 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 117.53 in Q1 2024 to a low of 4.08 in Q4 2023.
• Average Price to Sales over 5 years is 19.65, with a median of 15.78 recorded in 2022.
• Year-over-year, Price to Sales jumped 592.44% in 2024 and sank 89.49% in 2025.
• Over 5 years, Price to Sales stood at 13.77 in 2022, then sank by 70.35% to 4.08 in 2023, then surged by 405.34% to 20.63 in 2024, then tumbled by 34.59% to 13.5 in 2025, then rose by 12.0% to 15.12 in 2026.
• Per Business Quant data, the three most recent Price to Sales figures were 15.12 in Q2 2026, 21.17 in Q1 2026, and 13.5 in Q4 2025.